Cargando…

Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFpEF) roughly represents half of the cardiac failure events in developed countries. The proposed ‘systemic microvascular paradigm’ has been used to explain HFpHF presentation heterogeneity. The lack of effective treatments with few evidence-based ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campos-Martins, Alexandrina, Bragança, Bruno, Correia-de-Sá, Paulo, Fontes-Sousa, Ana Patrícia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417789/ https://www.ncbi.nlm.nih.gov/pubmed/34489711 http://dx.doi.org/10.3389/fphar.2021.724320

Ejemplares similares

Ion Fluxes through K(Ca)2 (SK) and Ca(v)1 (L-type) Channels Contribute to Chronoselectivity of Adenosine A(1) Receptor-Mediated Actions in Spontaneously Beating Rat Atria
por: Bragança, Bruno, et al.
Publicado: (2016)

The Ionotropic P2X4 Receptor has Unique Properties in the Heart by Mediating the Negative Chronotropic Effect of ATP While Increasing the Ventricular Inotropy
por: Bragança, Bruno, et al.
Publicado: (2019)

Comparison of Pharmacological Treatment Effects on Long-Time Outcomes in Heart Failure With Preserved Ejection Fraction: A Network Meta-analysis of Randomized Controlled Trials
por: Lin, Yaowang, et al.
Publicado: (2021)

Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction
por: Zhang, Liyun, et al.
Publicado: (2021)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
por: Tang, Yi, et al.
Publicado: (2022)

Traditional Chinese medicine for heart failure with preserved ejection fraction: clinical evidence and potential mechanisms
por: Fan, Yujian, et al.
Publicado: (2023)

Corrigendum: Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction
por: Zhang, Liyun, et al.
Publicado: (2022)

SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study
por: Lu, He, et al.
Publicado: (2023)

Efficacy and Safety of Qishen Yiqi Dripping Pill for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
por: Wang, Mengxi, et al.
Publicado: (2021)

Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction
por: Edelmann, Frank
Publicado: (2015)

Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk
por: Li, Jun-Feng, et al.
Publicado: (2023)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?
por: D’Antongiovanni, Vanessa, et al.
Publicado: (2021)

Predictive value of myocardial strain on myocardial infarction size by cardiac magnetic resonance imaging in ST-segment elevation myocardial infarction with preserved left ventricular ejection fraction
por: Wang, Qiang, et al.
Publicado: (2022)

Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction: State of the Art and Prospects for the Future
por: Fernandes, Sara Lopes, et al.
Publicado: (2020)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Assessing Strategies for Heart Failure with Preserved Ejection Fraction at the Outpatient Clinic
por: Jorge, Antonio José Lagoeiro, et al.
Publicado: (2014)

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
por: Liang, Bo, et al.
Publicado: (2022)

Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis
por: Xiang, Boyang, et al.
Publicado: (2022)

Sex differences in circulating proteins in heart failure with preserved ejection fraction
por: Stienen, Susan, et al.
Publicado: (2020)

Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure
por: Rueda, Patricia, et al.
Publicado: (2021)

Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction
por: Zordoky, Beshay N., et al.
Publicado: (2015)

Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction
por: Samson, Rohan, et al.
Publicado: (2016)

Animal models of heart failure with preserved ejection fraction
por: Conceição, G., et al.
Publicado: (2016)

Cell Therapy for Heart Failure With Preserved Ejection Fraction
por: Borlaug, Barry A., et al.
Publicado: (2016)

Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction
por: Nanayakkara, Shane, et al.
Publicado: (2018)

Modelling the complexity of heart failure with preserved ejection fraction
por: O’Gallagher, Kevin, et al.
Publicado: (2018)

Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction
por: Zeng, Heng, et al.
Publicado: (2019)

Heart Failure With Preserved Ejection Fraction: An Opportunity for Reflection
por: Gupta, Deepak K.
Publicado: (2017)

Strategies for management of heart failure with preserved ejection fraction
por: Winchester, David E.
Publicado: (2019)

Sarcopenic Obesity in Heart Failure With Preserved Ejection Fraction
por: Kirkman, Danielle L., et al.
Publicado: (2020)

Exercise echocardiography in aortic stenosis with preserved ejection fraction
por: Postolache, Adriana, et al.
Publicado: (2020)

Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
por: D’Amario, Domenico, et al.
Publicado: (2019)

Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction
por: Samson, Rohan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hjt85tja35itls9uv2r9khopps